NeOnc Technologies (NTHI) announced it has it has signed a definitive agreement for a $50M strategic partnership with Quazar Investment. The definitive agreement follows NeOnc’s Board unanimously approving the company’s participation in the contemplated $50 million equity investment and MENA region expansion, reflecting continued momentum. Under definitive agreement, Quazar intends to lead a capital formation round of up to $50 million, priced at $25 per share. The proposed structure allocates 70% of proceeds to the acquisition of NeOnc common stock, with 30% earmarked for launching clinical trials and building infrastructure across the UAE and broader MENA region.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTHI:
- NeOnc Technologies Signs Sub-License Agreement with NuroCure
- NeOnc Technologies Secures $5M Through Convertible Notes
- NeOnc Technologies executes sub-license agreement
- NeOnc Technologies Announces UAE Investment Partnership
- NeOnc Technologies approves $50M strategic partnership with Quazar Investment